This drug delivery system is a thermosensitive hydrogel with specific formation and degradation properties to facilitate sustained drug delivery of biologics, oligonucleotides (mRNA, DNA, etc.), and small molecules into the lymphatic system from needle injection for days to weeks. The hydrogel co-polymers are composed of FDA-approved materials, which are synthesized via simple chemical reactions to enable mass synthesis. They are environmentally resilient, allowing the chosen therapeutic agents to dictate the storage requirements (i.e., dry, wet, cold, or ambient conditions). Additionally, this system easily accommodates co-delivery of multiple agents and achieves high-level drug incorporation by simple mixing—eliminating the need for drug modifications that can reduce therapeutic agent activity. The targeted delivery approach substantially improves efficacy, while also allowing lower dosing and fewer administrations that improve patient safety. 

Systemic adverse effects are reduced, increasing the eligible patient pool and improving patient compliance. The system’s efficiency and simplicity reduce the high costs associated with immunotherapy. By directing therapies into the lymphatic system, it also opens new market opportunities for existing agents that can potentially extend patient life.